Company intelligence / Profile preview

Tceleron Therapeutics, Inc.

Ownership: Private
Development stage: Phase 2

Overview

Tceleron Therapeutics conducted a Phase 1/2 clinical trial (NCT05489991) for TmPSMA-02, a dually armored CAR T-cell therapy targeting PSMA in patients with metastatic castration-resistant prostate cancer. The trial was terminated and is currently overdue for reporting results as of May 2, 2024.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapy
Industry: Biotech

Drug pipeline

1 asset

eganelisib

Phase 2

Indications: Triple negative breast cancer, Head and neck squamous cell carcinoma, Urothelial cancer, Renal cell carcinoma

Beyond the preview

Go deeper on Tceleron Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tceleron Therapeutics, Inc..

Explore the full profile